KEAP1 and mesothelioma: Patients with cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), and stomach adenocarcinoma (STAD) with high KEAP1 expression and patients with adrenocortical carcinoma (ACC), acute myeloid leukemia (LAML), and LIHC with low levels of KEAP1 expression were predicted to have a high overall survival (Figure 1C).